Molbio Diagnostics, recently listed, posted a consolidated net profit of Rs 58.75 crore for the quarter ended June 30, 2026, marking a strong turnaround from a loss in the year-ago period. While revenue surged year-over-year to Rs 408.38 crore, the company noted a sequential decline from the previous quarter. The company is also managing an ongoing tax dispute involving Rs 20.87 crore.
Molbio Diagnostics Reports Q1 Net Profit of Rs 58.75 Crore
Revenue for the quarter stood at Rs 408.38 crore with a net profit of Rs 58.75 crore.
Reader Takeaway: Strong year-on-year turnaround despite sequential moderation; keep an eye on pending tax litigation developments.
What just happened
Molbio Diagnostics, which made its market debut on August 17, 2026, has released its first quarterly financial results as a public company for the period ending June 30, 2026. The firm recorded consolidated revenue from operations of Rs 408.38 crore, significantly higher than the Rs 99.71 crore reported in the same quarter last year. Net profit attributable to owners reached Rs 58.75 crore, compared to a loss of Rs 23.71 crore in the June 2025 quarter.
Why this matters
The results highlight a notable year-on-year growth trajectory for the diagnostics company. However, investors should note a sequential decline in both revenue and profit when compared to the quarter ended March 31, 2026, where the company reported revenue of Rs 560.62 crore and a profit of Rs 90.83 crore.
Corporate Developments
The board has streamlined its regulatory compliance process by authorizing key managerial personnel—CEO Sriram Natarajan, CTO Chandrasekhar Nair, CFO Manan Bimal Khokhani, and CS Darshan Karekar—to handle the materiality of corporate disclosures in line with SEBI standards.
Risks to watch
Molbio Diagnostics is currently contesting tax demands totaling Rs 20.87 crore, which include interest and penalties spanning assessment years 2020-21 through 2024-25. The company has appealed to the Commissioner of Income Tax and maintains that no financial adjustments are required at this stage given their strong defense.
What to track next
Investors should monitor the company's ability to normalize its quarterly performance following the post-IPO transition and watch for updates regarding the outcome of its income tax appeals.